inclusion criteria: - evidence of a positive sars-cov-2 test and test results received within the previous seven days - not currently hospitalized - willing and able to receive study drug by mail - willing and able to do the study questionnaires at baseline, day 3, 7, 14, 21 days via email or over the phone - no known allergy or other contraindication to macrolides - age 18 years or older at the time of enrollment - no known history of prolongation of the qt interval (eg. history of torsades de pointes, congenital long qt syndrome, bradyarrhthmia) - no recent use of hydroxychloroquine within the past 7 days for participants >55 years of age - not currently taking nelfinavir or warfarin (coumadin) - provision of informed consent - not currently pregnant

inclusion criteria: - evidence of a positive sars-cov-2 test and test results received within the previous seven days - not currently hospitalized - willing and able to receive study drug by mail - willing and able to do the study questionnaires at baseline, day 3, 7, 14, 21 days via email or over the phone - no known allergy or other contraindication to macrolides - age 18 years or older at the time of enrollment - no known history of prolongation of the qt interval (eg. history of torsades de pointes, congenital long qt syndrome, bradyarrhthmia) - no recent use of hydroxychloroquine within the past 7 days for participants >55 years of age - not currently taking nelfinavir or warfarin (coumadin) - provision of informed consent - not currently pregnant